The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

KEY WORD INDEX Keyword Index (Continued) High Definition Oscillometry .......... 561 high fat diet .......................... 2002, 2213 High Performance Metabolic Profiling ......................................... 1257 High Throughput ................... 316, 1813, 1894, 2553 high throughput screening ........ 333, 369 High throughput toxicity testing ........ 13 high-content screening assay ......... 1889 high-throughput ................................ 982 High-throughput assay ................... 2121 High-throughput Screening ........... 1760, 2505 hippocampus .... 1375, 1390, 2145, 2146 hiring .............................................. 2486 Histiotrophic nutrition .................... 1616 histone acetyltransferase .................. 107 histone H2AX .................................. 878 histone modification ..... 815, 1019, 2497 Histone Modifications .............. 946, 950 histopathology .................... 58, 560, 648 historical ......................................... 2437 Historical Control Data .................. 1028 history ............ 923, 924, 925, 926, 1880 history of safe use .......................... 1728 HIV gp120........................................ 677 HIV HLA........................................ 1364 HIV infection ................................... 612 HIV therapy.................................... 1275 HIV-antiretrovirals ........................... 613 HLA-specific .................................. 1498 HMGB1.......................... 263, 264, 2337 HMGCoA reductase ......................... 789 HMG-CoA Reductase Inhibitor ..... 1630 HNE ................................................. 262 HNSCC ............................................ 363 HO-1 .............................................. 2127 Homologous Recombination ........... 114 Homology modeling ........................ 368 Host defense ................................... 1474 Host resistance ............................... 1129 Hot flashes ..................................... 1219 house dust....................................... 1229 Housekeeping Gene Expression .... 1753 Hovenia dulcis extract .................... 2224 HPA axis ............................... 1699, 2151 HPLC/MS/MS................................ 1689 HPLC-MS/MS ............................... 1428 HR96 .............................................. 2382 Hras .................................................. 357 hRPTC............................................ 2544 HSP70 .............................................. 166 Hsp70 and liver .............................. 2199 HSP90 .............................. 214, 793, 804 HTS .................................................. 340 human ........ 474, 981, 1847, 1959, 1961, 2259 Human biotransformation .............. 2097 human bladder epithelial ................ 1977 Human blood plasma ..................... 2244 human bronchoalveolar H358 cells ...................................... 1681 human embryonic stem cells .......... 1167 human epidermal keratinocytes ..... 1176 human exposure level ...................... 435 Human Growth Hormone .............. 1156 human health risk assessment ....... 1229, 1266 human health risks ......................... 1245 Human Hepatocytes ..... 381, 1094, 2096 human keratinocyte cell line ......... 1011, 2059 human kinetic adjustment factor ..... 500, 501 human liver slices .......................... 2561 human lung cells ............................ 1831 human lymphocytes ......................... 326 human metabolism ............... 1823, 1824 human neural progenitor cells .......... 870 612 SOT 2011 ANNUAL MEETING Human Peripheral Blood Lymphocytes .................................... 334 human placenta .............................. 2169 human plasma ................................ 2195 human primary hepatocytes ............. 859 Human Relevance .......................... 1933 human renal proximal tubule cells ... 762 human skin equivalents .................. 1012 human stem cell ............................. 2455 human stem cell-derived cardiomyocyte ................................ 1165 human THP-1 macrophages ........... 2053 human variability ............................. 821 humanized mAb ............................. 1929 humoral immunity ............................ 678 Huntington’s disease ............ 2121, 2132 huperzine A .................................... 2585 HUVECs ........................................ 1999 hydrocarbons .................................. 2316 hydrofluorocarbon .......................... 2259 hydrogen peroxide ......................... 1532 Hydrogen Sulfide ........................... 1214 hydroquinone ................................. 1673 hydroxyl radicals ............................ 1292 hydroxylated fullerene nanoparticles .................................. 1176 hydroxylated PBDEs ...................... 1607 Hypercholesterolemia .................... 1113 hypercholesterolemic ..................... 1112 hyperoxia .... 261, 264, 1856, 2193, 2587 hypersensitivity ......... 83, 470, 620, 667, 989, 1497, 1498, 2422 Hypertension .................. 199, 554, 2008 Hyperthyroidism ............................ 2353 hypertrophy ...................................... 207 Hypotension ..................................... 778 hypothalamic peptide ..................... 2343 hypothalamic-pituitary-thyroid ........ 702 Hypothalamus ...................... 1063, 2354 Hypothesis Generation ..................... 480 Hypothyroidism ............................. 2353 hypoxia ........................................... 1652 IATA ............................................... 1539 ICAM-1 ............................................ 259 ICH S6 ........................................... 1912 ICH S9 ........................................... 1912 ID gene ............................................. 445 idiosyncratic drug reactions .... 424, 509, 1499, 1501, 1504 Idiosyncratic Hepatotoxicity ........... 936, 1014, 1658 Idiosyncratic Liver Toxicity ............. 510 IE-Cpr-Null .................................... 2264 IFN-gamma ...................................... 694 IgE ................................ 530, 2080, 2207 IgE antibody ..................................... 903 IgE+ B lymphocytes ........................ 530 IGF-1 ........................................ 351, 407 IGF-1R ................................... 788, 2315 IL-1 Beta .............................. 1040, 1617 IL-12 ................................................ 796 IL-18 .............................................. 2571 IL-1b .................................................. 57 IL-2 .................................................. 345 IL-23 ................................................ 796 IL-33 .............................................. 1514 IL-6 .......................................... 441, 442 IL-7 ................................................ 1502 ILSI ................................................ 1525 image ................................................ 448 Image analysis ................................ 2615 Imaging .................................. 429, 2618 immune cells ........................ 1141, 1891 Immune function .............................. 658 immune monitoring for latent viruses ............................................ 1148 Immune regulation ................... 680, 949 immune response ........................... 2042 immune responses .............................. 23 immune suppression ............... 678, 1013 immune system .............................. 1189 immune tolerance ........................... 1502 immune-competent cells ................ 2052 Immune-mediated toxicity ............. 2686 immune-modulating ....................... 2083 Immunodeficient mice ................... 1512 immunodevelopment ........................ 630 immunogenicity ................... 1150, 1151 Immunoglobulin regulation ........... 1124 Immunohistochemistry .................... 881 immunolocalization .......................... 575 immunological mechanisms ............. 902 immunology ................. 657, 1126, 2446 immunomodulation ................ 698, 1169 Immunomodulator ............................ 692 Immunomodulatory compounds .... 1140 immunopathology .......................... 1709 Immunophenotyping ............... 528, 529, 650, 651 immunosuppression .......... 80, 652, 659, 667, 675, 676, 1133, 1189 immunotoxic .................................... 695 immunotoxicity ....................... 185, 649, 650, 654, 659, 661, 663, 667, 670, 679, 682, 691, 1125, 1131, 1133, 1140, 1145, 1146, 1628, 1988, 1989 Immunotoxicity testing .................... 664 immunotoxicology .......... 287, 571, 653, 655, 673, 1143, 1147, 1148, 1152, 1504, 2422, 2682, 2685 impedance ...................................... 2344 Implant ................................................. 1 Imposex ................................ 1068, 2393 improved catheter dosing ............... 1913 in ovo .............................................. 1684 in silico ....... 157, 469, 1559, 2679, 2681 in silico analysis ............................... 132 in silico model .......................... 137, 464 in silico prediction .................... 496, 855 In situ perfusion ............................. 1377 in utero ........................................... 1612 in utero exposure .......... 616, 1055, 1069 in vitro ..... 640, 803, 850, 939, 969, 978, 982, 990, 1002, 1020, 1023, 1354, 1539, 1553, 1650, 1671, 1821, 1888, 1908, 1966, 2070, 2167, 2303, 2454, 2463, 2516, 2543, 2544, 2550, 2554, 2629, 2678, 2679 in vitro-in vivo extrapolation ............. 13, 715, 1975 in vitro airway model ..................... 1003 in vitro alternative .......................... 2373 in vitro Alternative Method ...... 87, 1010 in vitro Alternatives ...... 998, 1528, 2032 in vitro Animal Alternative Method ................................. 1049, 1555 in vitro assay ........................ 1000, 2540 in vitro assays ..................................... 28 in vitro biliary clearance................. 1081 in vitro cornea model .......... 2031, 2032, 2033 in vitro cytotoxicity .... 1021, 1234, 2226 in vitro developmental neurotoxicity testing ....................... 2518 in vitro drug testing .............. 1165, 1899 in vitro evaluation platform ............ 2158 in vitro Gastrointestinal Model ...... 2572 in vitro human skin model ............... 647 in vitro Human Skin Models ......... 2541, 2542 in vitro-in vivo correlation ...... 856, 2348 in vitro-in vivo extrapolation ............ 733 in vitro method comparison ............. 565 in vitro Methodology ....................... 905 in vitro methods ................................. 14 in vitro methylation ........................ 1981 in vitro Micronucleus ............... 32, 2162 in vitro micronucleus assay .............. 343 in vitro model ............ 1009, 1902, 2370, 2513, 2519 In vitro model for inhalation ........... 983, 2567 in vitro model for vapor exposure ......................................... 2304 in vitro models ....................... 430, 1766 in vitro neurotoxicity .......................... 31 in vitro prediction ..................... 317, 935 in vitro screening ........... 717, 996, 1897, 2564, 2680 in vitro skin .................................... 2574 in vitro skin irritation ............. 467, 2555 in vitro skin model ..... 2534, 2571, 2575 in vitro skin sensitization test ... 85, 2560 in vitro test ..................................... 1010 in vitro testing .... 739, 1905, 2470, 2480 in vitro toxicity assays ......... 1094, 1889, 1903 in vitro Toxicology ................. 534, 1606 in vivo ..... 1045, 1470, 1562, 2234, 2261 in vivo alternative ............................. 341 in vivo comet/micronucleus combination .................................... 1481 in vivo gene mutation ..................... 2632 in vivo imaging ............................... 2674 in vivo micronucleus ...................... 1416 in vivo model .................................. 1018 in vivo mutation ...................... 879, 1416 inbred mouse strain .......................... 822 Indirubin ........................................... 416 Indium particles ............................... 578 individualized prevention strategies .. 46 indoles ............................................ 1507 indoor ............................................. 1244 indoor air pollutant biomonitoring ... 977 Indoor Air Quality ...... 1214, 1215, 1573 Indoor dust ..................................... 1268 indoor mold ...................................... 174 Induced Pluripotent Stem Cell ........ 215, 1173, 2453 induced pluripotent stem cells ...... 1167, 2451 inducible nitric oxide synthase ......... 684 Infants ............................................ 1060 inflammasome .............. 27, 35, 55, 1711 Inflammation ....... 55, 61, 217, 218, 238, 254, 314, 416, 452, 539, 599, 643, 668, 669, 756, 901, 1091, 1105, 1128, 1134, 1294, 1462, 1709, 1780, 1782, 1784, 1785, 1997, 2028, 2127, 2181, 2190, 2205, 2323, 2331, 2446 inflammatory bowel disease .... 36, 1133 inflammatory bowel diseases ........... 364 Inflammatory cytokines ................. 1570 inflammatory response ..................... 573 inflammatory responses ..................... 25 influenza ......................................... 1132 Informatics ....................................... 419 infusion models .............................. 1931 Ingenuity Pathway Analyses .............. 26 Inhalation ........ 290, 540, 563, 564, 589, 594, 599, 601, 605, 1152, 1196, 1458, 1546, 1570, 1755, 1762, 1882, 1954, 2012, 2475, 2476, 2493 Inhalation dose ................................. 572 Inhalation elicitation threshold ........ 904 Inhalation exposure ..... 588, 1471, 2029, 2610 inhalation exposures ....................... 2338 Inhalation nanotoxicology ............. 1466 Inhalation Risk Assessment ............. 587 Inhalation Safety Assessment ......... 585, 587 Inhalation study .............................. 1459 inhalation toxicity ...... 1547, 2057, 2567 Inhalation toxicology .......... 53, 58, 585, 586, 587, 1468 Inhaled .................................. 1883, 2058 inhibition ........................................ 1844 initiation/promotion ............... 237, 2630 Injection ......................................... 1902
Keyword Index (Continued) innate immune system .................... 2196 Innate Immunity ............. 256, 673, 1990 inorganic arsenic .......... 550, 1998, 2655 insecticide ...................................... 1343 Insecticides ........................... 1227, 1353 Inspector Toxicology ...................... 1865 Instillation ...................................... 1458 Insulin .............................................. 811 insulin release ................................... 267 insulin signaling ............................. 2001 Insuline Resistance ......................... 2201 Intake .............................................. 1228 Integrated Testing Strategy .............. 858 integration ...................................... 1918 integrative ........................................ 939 integrative approach ... 2512, 2513, 2515 interleukin 17 ..................................... 93 interleukin 8 ................................... 2527 interleukin-1 ....................................... 35 international harmonization ........... 2157 International Treaties ..................... 1310 Interspecies extrapolation ................ 920 intervention .................................... 2582 Interview preparation ..................... 2485 intestinal bacteria ........................... 2221 intestinal metabolism ..................... 1825 Intestinal P450 ............................... 2264 Intracellular trafficking .................... 382 intracerebroventricular ..................... 801 Intramuscular injection .................... 648 intranasal instillation ...................... 1761 Intratracheal instillation ......... 590, 2331 intravenous ....................................... 617 Intravenous infusion ....................... 1931 Intraventricular conduction delay ............................................... 2114 Intravitreous administration ........... 1927 intravitreous injection ...................... 546 investigational toxicology .............. 1592 iodine .............................................. 2608 ion cyclotron resonance mass spectrometry ....................................... 44 Ionic Liquids .................................. 1578 Ionizing radiation ............. 63, 879, 2605 IPS cell cardiomyocytes ................. 1161 iPSCs .............................................. 2454 IQ ..................................................... 626 IRIS ................................................ 1958 Iron Homeostasis ............................. 603 iron metabolism ............................... 511 Iron Oxide ...................................... 2166 Iron transport .......................... 269, 1651 Iron Uptake .................................... 1649 Irritation ............................... 1947, 2535 ischemia reperfusion ...................... 1651 Ischemic Reperfusion Injury .......... 1274 islet ................................................. 2653 ISO Standard 10993 ....................... 1550 Isodecyl benzoate ........................... 1029 Isomalathion ................................... 1336 Isophorone ...................................... 2346 isoproterenol .................................. 1907 Itch ..................................................... 70 IVOS .............................................. 1050 Jacketed external telemetry .............. 559 JAK2 ................................................ 403 JET jacketed external telemetry ....... 557 JMJD1A ........................................... 816 JNK .................................................. 299 job .................................................. 2482 Job Market Survey ......................... 1879 jobs ....................................... 2481, 2486 JP-8 jet fuel ...................................... 160 juvenile ..................................... 619, 630 Juvenile dog ..................................... 779 Juvenile testing ................................. 195 Juvenile Toxicity ............... 15, 618, 622, 623, 662 K–12 ........................... 1866, 1867, 1868 K–12 education .............................. 1869 Kainate ................................... 399, 1297 Kava extract ..................................... 454 Keap1 ............................411, 1116, 1787 keratinocyte .............................. 631, 892 keratinocyte metabolism .................... 88 keratinocytes .......................... 349, 1753 Kernicterus ....................................... 386 ketamine ............................... 1614, 2597 key event ........................................ 1721 kidney ...... 744, 747, 752, 754, 757, 760, 761, 764, 765, 767, 768, 769, 772, 774, 1434, 1594, 2282, 2313, 2544 kidney biomarkers .......................... 1439 Kidney Injury ....................... 1300, 1648 kidney injury molecule 1 ................. 759 kidney toxicity ............................... 1439 KIM-1 ............................................ 1602 kinase enrichment analysis ............ 1738 kinase inhibitors ............................. 1172 kinase therapeutics ........................... 401 Kinases ................................... 150, 1906 Kinetics ........................ 709, 1232, 2610 Kisspeptin ...................................... 1063 KIT ................................................. 1054 Knockdown-mice ............................. 553 Knockout mice ................................. 230 knockout mouse ............................... 885 knowledge base ................ 155, 427, 934 Knowledgebase ................................ 728 KRAS ............................................... 239 K-ras ....................................... 879, 2632 Kupffer cells ........................... 430, 1092 L1 Retrotransposon .......................... 406 L6 myoblasts .................................. 1890 Label .............................................. 2410 lactate dehydrogenase .................... 1447 Lactating rat and pup ..................... 2668 Lactation ........................................ 1031 lactoferrin ........................................... 95 LAMP-2 ......................................... 1452 Langerhans cell .................................. 94 Langerhans cells ................................. 95 laser scanning cytometry ................ 1899 LC/MS/MS ..................................... 2424 LC/MS-MS .................................... 2383 LC50 .............................................. 2236 LC-ESI-MS .................................... 1669 LC-MS/MS ...... 2195, 2284, 2285, 2416 LD50 .............................................. 2577 Lead ................................. 294, 295, 296, 686, 835, 1204, 1205, 1533, 1698, 1699, 1841, 2138, 2142, 2143, 2145, 2146, 2150, 2187, 2397 Lead (Pb) .......... 1697, 1701, 2144, 2151 Lead Exposure ....................... 943, 2147 lead, pb ............................................. 626 Learning ......................................... 1875 Learning and Memory .......... 1646, 2617 Lectin ............................................. 2223 Leflunomide ........................... 432, 1610 left ventricular pressure .................. 1930 Leiomyoma .................................... 1070 let-7g ................................................ 383 Lethargic ........................................ 1385 Letrozole ........................................ 2361 leukemia ........... 1941, 1944, 1949, 2340 Leukemia Therapy ......................... 1887 Leukotrienes ................................... 1192 levomethorphan .............................. 1100 Leydig cells .................................... 2552 Libby Amphibole ... 601, 602, 603, 1511 life span low dose alcohol exposure ............................... 1640, 2613 Lifecycle ........................................ 1594 ligand-induced activation ............... 1634 Ligand-Protein complex ................... 149 lindane ............................................ 2562 LINE .................................................. 99 lipid ................................................ 1115 Lipid peroxidation .......................... 2423 Lipid Trafficking ............................ 1282 lipidomics ....................... 551, 875, 1426 lipids ............................................... 2531 lipoatrophy ..................................... 1156 Lipopolysaccharide .................. 170, 516 Lipopolysaccharide (LPS) ...... 171, 688, 1450 lipopolysaccharides ........................ 1169 Liposomal-NAC ............................. 1269 Lipoxygenase ................................. 1192 liver ......................... 140, 142, 270, 365, 375, 392, 426, 430, 440, 452, 455, 456, 461, 462, 1004, 1083, 1098, 1099, 1102, 1103, 1109, 1112, 1115, 1311, 1502, 1503, 1603, 1641, 1643, 1788, 1853, 2002, 2079, 2109, 2237, 2245, 2282, 2404, 2496, 2516, 2532, 2553, 2631 liver cancer ..................................... 2642 Liver Cancer ..................................... 945 liver carcinogenesis .......... 223, 874, 875 Liver Disease ................................. 1958 Liver fibrosis .................................. 2509 Liver function ................................. 1909 liver hypertrophy .................. 1090, 2657 Liver injury ................. 434, 1084, 1093, 1101, 1648 Liver Regeneration ......................... 1091 Liver Slices ............................ 421, 1830 Liver Toxicity ... 1088, 1106, 2074, 2543 Liver tumor ...................................... 224 Livestock waste ................................ 229 LLNA ............ 82, 83, 91, 907, 963, 989, 1518, 1519, 1520, 2536 LNTE ............................................. 1676 Local lymph node ............................ 468 Local Lymph Node Assay .................. 82 local lymph node assay (LLNA) ........ 81 Local Tolerance .............................. 1922 Locomotion .................................... 1742 Locomotor activity ......................... 2615 long term effect .............................. 1334 long-term ........................................ 1913 Long-term estrogen exposure .......... 103 long-term peak exposure ................ 1226 Lovastatin ....................................... 2264 Low Dose ............................... 404, 1697 low dose linearity ........................... 1962 Low dose radiation ......................... 2593 low-dose linearity ............................. 475 loxapine ................................ 1882, 1883 LPS ........................................... 443, 686 Luminex xMAP ................................ 743 Lumping ........................................... 718 Lunar Dust ............................... 303, 304 lung ................. 268, 272, 289, 539, 617, 884, 885, 1179, 1188, 1191, 1195, 1463, 1752, 1759, 2082, 2300, 2333, 2334, 2489, 2492 Lung cancer .......... 249, 286, 1185, 2521 lung cancer cell migration ................ 383 lung cell .......................................... 1181 lung cells ........................................ 1601 Lung development ......................... 2193 lung diseases .................................. 2477 lung dosimetry ............................... 2289 Lung epithelial cells ......................... 300 Lung Fibrosis ...... 53, 1293, 1294, 1454, 2081, 2160 lung function .......................... 541, 1762 Lung function measurement .......... 2326 Lung inflammation .... 1193, 1474, 2051, 2328, 2487 lung injury .................. 24, 56, 567, 2038 lung metabolism ............................. 1849 lung modeling ................................ 2299 Lung slice ......................................... 988 lung toxicity ................................... 1901 Luteinizing hormone ...................... 2552 lymph node ....................................... 288 Lymphoblastoid.............................. 2447 Lymphocryptovirus ........................ 1149 lymphocyte ....................... 337, 656, 665 lymphocytes ................................... 2226 lyophilization ................................... 893 Lysosome ....................................... 1650 lysosomes ....................................... 2533 lysyl oxidase ..................................... 219 MABEL ............................................ 803 Macrophage ........... 258, 578, 682, 1127, 1128, 1272, 1711, 2161 macrophage activation ..................... 456 macrophages ..... 457, 1136, 1709, 1710, 1712, 1713, 1714 macrophages activation .................... 878 maghemite ...................................... 2170 magnetic nanoparticle .................... 1475 magnetic tracking ............................. 514 Magnetite ......................................... 328 Mainstream cigarette smoke ............ 983 MALDI Imaging Mass Spectrometry .................................. 1285 male infertility ................................ 1053 Male Reproductive ............................. 62 malignant mesothelioma .................... 27 Mammary Cancer ............................. 231 Mammary Gland .................. 1612, 1622 mancozeb ............................. 1356, 2087 maneb ...... 625, 1222, 1349, 1350, 1351, 2087 manganese ....... 173, 312, 625, 629, 701, 845, 1102, 1222, 1237, 1238, 2122, 2123, 2124, 2125, 2128, 2131, 2132, 2135, 2136, 2139, 2140, 2141, 2148, 2149, 2317, 2456, 2457, 2458, 2459, 2460, 2461, 2579, 2580, 2591, 2592, 2664 Manganese Exposure ..................... 2137 manganese nanoparticles ............... 2182 manganese neurotoxicity .... 2129, 2130, 2133 Manganese transport ...................... 2121 Manganism ....... 2125, 2579, 2580, 2591 mannan ............................................. 253 mannan binding lectin ...................... 253 manufactured engineered nanomaterials ................................... 846 manufactured gas plants ................. 1236 Manuscript ..................................... 1768 MAP kinase .................................... 2036 MAPK .................... 118, 244, 402, 1393 Mapping ........................................... 857 margin of exposure............... 1565, 2295 Marin County CA ............................. 229 Marine mammal ............................... 658 Marine Mammals ........................... 2407 marine pollution ................... 1870, 2252 marine product ............................... 2219 marker for developmental retardation ...................................... 1640 Markov Chain Monte Carlo (MCMC) .......................................... 722 mars dust .......................................... 304 MASOT .......................................... 1865 Mass Spectrometry ...... 408, 1257, 1578, 1682, 2011, 2017 mass transfer .................................... 632 mast cell ........................................... 254 mast cells ........................................ 1500 Maternal ......................................... 1615 maternal dietary intake ................... 1636 Maternal-fetal toxicity ................... 1075 Mathematical Modeling ....... 1240, 2069 matrix metalloproteinase .................. 132 matrix metalloproteinase-9 ............ 2208 matrix metalloproteinases .............. 2081 MCF-7 cells ................................... 2371 MCTT HCE model........................... 975 MDMA ................................. 1306, 1829 Mdr1a ............................................... 535 MDSCs ............................................. 676 SOT 2011 ANNUAL MEETING 613 KEY WORD INDEX
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIODEGRADABLE MATERIALS FOR TISSU
Page 7 and 8:
that genetic toxicology data are ge
Page 9 and 10:
well-orchestrated lung inflammation
Page 11 and 12:
scribed in the literature. We have
Page 13 and 14:
years ago). We will illustrate how
Page 15 and 16:
involved in the biodegradation proc
Page 17 and 18:
stem cells but rather a treatment i
Page 19 and 20:
additional compound showed agreemen
Page 21 and 22:
82 COMPARISON OF 3H-THYMIDINE INCOR
Page 23 and 24:
irritants. While in practice these
Page 25 and 26:
alleles are especially vulnerable t
Page 27 and 28:
109 CD4+ T CELL INTRINSIC TNF RECEP
Page 29 and 30:
118 TO STUDY THE SIGNAL TRANSDUCTIO
Page 31 and 32:
PAHs, such as dioxins, are prevalen
Page 33 and 34:
containing substituents and/or hydr
Page 35 and 36:
146 COMPUTATIONAL MODELING FOR QT P
Page 37 and 38:
suggest that the combination of too
Page 39 and 40:
164 TRANSLOCATOR PROTEIN (18 KDA) (
Page 41 and 42:
function as a metal binding protein
Page 43 and 44:
laboratory has demonstrated that NR
Page 45 and 46:
known. The aim of this study was to
Page 47 and 48:
from 5 to 28 days in duration) in e
Page 49 and 50:
positive cells, caspase-3 activatio
Page 51 and 52:
creased level in the 46 kDa preproe
Page 53 and 54:
invasiveness at concentrations repr
Page 55 and 56:
thracene (DMBA,50 μg in acetone, a
Page 57 and 58:
247 CO-CARCINOGENESIS OF N, N- DIET
Page 59 and 60:
sponds to the endosomal dsRNA that
Page 61 and 62:
ODD in both WT (maximum 177% of con
Page 63 and 64:
Lastly, using p53siRNA cells, p53 w
Page 65 and 66:
its receptor Mpl to exert its funct
Page 67 and 68:
294 LOW LEVEL OF LEAD CAN INDUCE PH
Page 69 and 70:
lunar surface presented potential h
Page 71 and 72:
lar about cellular export mechanism
Page 73 and 74:
DNA in the kidney medulla, grandula
Page 75 and 76:
5.00 and 7.50 mg/kg/day by oral gav
Page 77 and 78:
events and carcinogenesis. Here we
Page 79 and 80:
tinization of cells of the hair fol
Page 81 and 82:
358 CHARACTERIZATION OF GENOME-WIDE
Page 83 and 84:
RNAi were also performed to identif
Page 85 and 86:
376 A FUNCTIONAL CROSSTALK BETWEEN
Page 87 and 88:
UGT1A gene induction, while this re
Page 89 and 90:
tivity, specifically peroxisome pro
Page 91 and 92:
and cytotoxic effects; however, its
Page 93 and 94:
histone deacetylase that is necessa
Page 95 and 96:
ment. Paradoxically, buthionine sul
Page 97 and 98:
drug leflunomide and its major (A77
Page 99 and 100:
442 GENE EXPRESSION AND MORPHOLOGIC
Page 101 and 102:
451 INHIBITION OF THE MITOCHONDRIAL
Page 103 and 104:
460 SULFORAPHANE PREVENTS ACETAMINO
Page 105 and 106:
drophilic/lipophilic balance. Other
Page 107 and 108:
pharmacokinetic and toxicological p
Page 109 and 110:
489 USE OF ‘OMICS DATA TO IMPROVE
Page 111 and 112:
498 APPLICATION OF AGE-SPECIFIC ADJ
Page 113 and 114:
507 A DOSE VOLUME TOLERABILITY STUD
Page 115 and 116:
involved the use of an acute inflam
Page 117 and 118:
sorption in the gastrointestinal (G
Page 119 and 120:
(ABC) transporters actively transpo
Page 121 and 122:
545 BEHAVIORAL EFFECTS OF REPIN IN
Page 123 and 124:
a blood pressure phenotype that res
Page 125 and 126:
and inhalation exposure system that
Page 127 and 128:
and lethality associated with these
Page 129 and 130:
position, on vascular reactivity an
Page 131 and 132:
therefore more accurate and reprodu
Page 133 and 134:
commercial chrysotile product that
Page 135 and 136:
elative to their controls. ST-depre
Page 137 and 138:
ats. The majority of the studies fo
Page 139 and 140:
in the China Jintan Child Cohort St
Page 141 and 142:
corneum thickness, cellular epiderm
Page 143 and 144:
645 EVALUATION OF THE IN VITRO EPIS
Page 145 and 146:
654 TCDD ADSORBED ONTO NATURAL AND
Page 147 and 148:
tion revealed no test article-relat
Page 149 and 150:
671 INFLAMMATION AND TISSUE DAMAGE
Page 151 and 152:
model, ethanol was found to inhibit
Page 153 and 154:
689 ENHANCED SUPPRESSIVE FUNCTION O
Page 155 and 156:
NAC + LPS yielded different levels
Page 157 and 158:
707 LIFE-STAGE PBPK MODELS FOR MULT
Page 159 and 160:
downstream of the apical endpoint o
Page 161 and 162:
726 UPDATED ALUMINUM PHARMACOKINETI
Page 163 and 164:
global parameter sensitivity analys
Page 165 and 166:
and renal inflammation induced by 2
Page 167 and 168:
754 PLASMA, URINE, AND TISSUE CONCE
Page 169 and 170:
cently characterized transporter OA
Page 171 and 172:
exposure system was developed from
Page 173 and 174:
lood cell mass and decrease in urin
Page 175 and 176:
practical alternatives to MC in non
Page 177 and 178:
imals dosed with 167 mg/kg THU alon
Page 179 and 180:
and organ weights, clinical signs a
Page 181 and 182:
yet is induced in most bladder and
Page 183 and 184:
830 RISK ASSESSMENT OF THE SPILL: C
Page 185 and 186:
knowledgebase creation. Results are
Page 187 and 188:
852 UNDERSTANDING STRUCTURAL AND PH
Page 189 and 190:
for integrating epidemiology and an
Page 191 and 192:
motor activity, including age of th
Page 193 and 194:
y partial purification of urine (fr
Page 195 and 196:
pacity for self-renewal and may dif
Page 197 and 198:
sue. The depth of our analysis led
Page 199 and 200:
910 IMPLEMENTING CALIFORNIA’S GRE
Page 201 and 202:
concentrations in six tissues and b
Page 203 and 204:
934 THE FDA’S LIVER TOXICITY KNOW
Page 205 and 206:
943 GENOME-WIDE DNA METHYLATION DIF
Page 207 and 208:
membrane localization and subsequen
Page 209 and 210:
trols, respectively. Subtoxic and t
Page 211 and 212:
survival using both smoking regimes
Page 213 and 214:
as non-, weak, moderate, or strong
Page 215 and 216:
988 NNK-INDUCED CYTOKINE ALTERATION
Page 217 and 218:
group (one-way ANOVA, p90 % viabili
Page 219 and 220:
ered as an organ involved in xenobi
Page 221 and 222:
Transport of CPZ across the Caco-2
Page 223 and 224:
estrous cycle and sexual behavior d
Page 225 and 226:
mRNA expression levels. Collectivel
Page 227 and 228:
1043 THE EFFECTS OF ENDOCRINE DISRU
Page 229 and 230:
1052 MONO-2-ETHYLHEXYL PHTHALATE IN
Page 231 and 232:
Results: MC was variable within and
Page 233 and 234:
UtSMCs. Phosphorylation of FoxO1 wa
Page 235 and 236:
nonpregnant and pregnant diabetic m
Page 237 and 238:
1089 PFOA-INDUCED LIVER EFFECTS IN
Page 239 and 240:
events in the liver. AZD9056 was ev
Page 241 and 242:
The peppermint oil caused a concent
Page 243 and 244:
OA did not affect food consumption.
Page 245 and 246:
1126 PERSISTENT DEVELOPMENTAL ARYLH
Page 247 and 248:
1135 BACH2 BINDING TO Prdm1 AS A ME
Page 249 and 250:
The purpose of this project was to
Page 251 and 252:
one marrow. Since Chk1 is an attrac
Page 253 and 254:
1163 THE MRNA AND MIRNA PROFILE OF
Page 255 and 256:
have now compared the IC50 values b
Page 257 and 258:
1181 ELUCIDATION OF FACTORS DETERMI
Page 259 and 260:
enced by pre-exposure to cigarette
Page 261 and 262:
if abnormal PF was associated with
Page 263 and 264:
weight (P=0.016) and small for gest
Page 265 and 266:
portant cause of death, compared to
Page 267 and 268:
posure groups. However, the differe
Page 269 and 270:
Naphthalene is routinely analyzed i
Page 271 and 272:
1245 SEASONAL CHARACTERIZATION OF H
Page 273 and 274:
1255 URINARY T, T MUCONIC ACID LEVE
Page 275 and 276:
modating a reliable data evaluation
Page 277 and 278:
enzoquinone generate ROS and arylat
Page 279 and 280:
teins (e.g. C3, 4, and 5, APOB, VDB
Page 281 and 282:
1293 TRANSFORMING GROWTH FACTOR BET
Page 283 and 284:
mation was decreased to the same le
Page 285 and 286:
1312 EVALUATION OF THE SENSITIVITY
Page 287 and 288:
luted OFR and CRL. Culture media ex
Page 289 and 290:
urinary TCPy levels, blood and brai
Page 291 and 292:
activity. The dose-response curves
Page 293 and 294:
mice, each with 4 dose groups. One
Page 295 and 296:
exposure to both ATR and DACT has a
Page 297 and 298:
third tetratricopeptide repeats (TP
Page 299 and 300:
7d. 28d after TMT injury there was
Page 301 and 302:
subunits. Each cell type was treate
Page 303 and 304:
1394 COMPARATIVE EFFECTS OF METHYLM
Page 305 and 306:
1403 GENOTOXICITY AND PRE-NEOPLASTI
Page 307 and 308:
vated only in high-dose-treated ani
Page 309 and 310:
1421 DOSE-RESPONSE OF NAPHTHALENE-I
Page 311 and 312:
cisplatin; 1.2-, 1.9- and 2.9-fold
Page 313 and 314:
Day 11 and started to recover on Da
Page 315 and 316:
1448 DEVELOPMENT OF A METHOD FOR QU
Page 317 and 318:
1457 GLOBAL GENE PROFILING REVEALS
Page 319 and 320:
cluding mouse and human macrophage,
Page 321 and 322:
model of lung inflammation and host
Page 323 and 324:
1484 NANOTOXICOLOGY AND NANOHEALTH
Page 325 and 326:
throughput in vitro approach was us
Page 327 and 328:
1502 IMMUNOLOGICAL ASPECTS OF AN AN
Page 329 and 330:
(CIA) and the Streptococcal cell wa
Page 331 and 332:
sitizers were 100% concordant among
Page 333 and 334:
1530 MINIMAL RISK LEVELS FOR STYREN
Page 335 and 336:
ical groups in the field of regulat
Page 337 and 338:
vitro with this potentially insect-
Page 339 and 340:
their performance on toxicological
Page 341 and 342:
need for a better understanding of
Page 343 and 344:
1577 AN IN VITRO MODEL SYSTEM FOR A
Page 345 and 346:
gene expression post-transcriptiona
Page 347 and 348:
1595 GENE EXPRESSION PROFILE OF RAT
Page 349 and 350:
to confirm a hepatotoxic property o
Page 351 and 352:
1613 AN INVESTIGATION OF THE CLEARA
Page 353 and 354:
its nuclear translocation was reduc
Page 355 and 356:
were collected from TK animals at d
Page 357 and 358:
egulated targets were selected for
Page 359 and 360:
U/L after tetracycline. Minocycline
Page 361 and 362:
peri-pubertal FasL-/- mice show a d
Page 363 and 364:
showed similar levels of apoptosis
Page 365 and 366:
1676 TWO BIOMARKERS FOR EVALUATION
Page 367 and 368:
motifs selected. This system was ap
Page 369 and 370:
1693 VOC SERUM LEVELS IN THE GENERA
Page 371 and 372:
1702 DOES THE CLOCK MAKE THE POISON
Page 373 and 374:
those with high nickel content are
Page 375 and 376:
isk assessment. However, unique cha
Page 377 and 378:
model of APAP metabolism and glutat
Page 379 and 380:
logically & morphologically similar
Page 381 and 382:
posure, blood chemistry was analyze
Page 383 and 384:
elated to oxidative stress by measu
Page 385 and 386:
ostasis), but work is needed to tra
Page 387 and 388:
tokine products during carcinogenes
Page 389 and 390:
ways as chemical stressors and, the
Page 391 and 392:
toxicity of nanomaterials relates s
Page 393 and 394:
1815 MEASURING COMPOUND SELECTIVITY
Page 395 and 396:
1825 EFFECTS OF METABOLISM BY INTES
Page 397 and 398:
cyanoacetic acid increased 2-3 fold
Page 399 and 400:
1845 IS THE PROMISCUITY OF THE ARYL
Page 401 and 402:
crorarray analysis. RT-PCR results
Page 403 and 404:
are a family of phase-II biotransfo
Page 405 and 406:
ous labs. As a result of positive s
Page 407 and 408:
down the doses may produce more tox
Page 409 and 410:
spectively. Below 100 mg/l of gemfi
Page 411 and 412:
1900 GENERATION OF PRECISION CUT LI
Page 413 and 414:
iomarkers or observation of lesions
Page 415 and 416:
creased reticulocytes and lymphocyt
Page 417 and 418:
statistically significant interacti
Page 419 and 420:
monize sample preparation and analy
Page 421 and 422:
NPC and sinonasal cancer in neighbo
Page 423 and 424:
showed incidences of lung and nasal
Page 425 and 426:
utylbenzenes, exhibited most simila
Page 427 and 428:
1975 DIFFERENTIAL MODULATION OF CYP
Page 429 and 430:
organic As to MMA(V) and a lower ca
Page 431 and 432:
ole in invasion and metastasis of c
Page 433 and 434:
3T3-L1 cells to low-levels of arsen
Page 435 and 436:
2011 IDENTIFICATION OF A NOVEL VX M
Page 437 and 438:
This work was supported by Cooperat
Page 439 and 440:
2029 EFFICACY OF ENDOTRACHEAL ADMIN
Page 441 and 442:
Diazepam injections and its combina
Page 443 and 444:
2047 ESTERASE ACTIVITIES AND HEMOST
Page 445 and 446:
nanoparticle-induced toxicity progr
Page 447 and 448:
house, were iv infused into rats ov
Page 449 and 450:
een explored. This study investigat
Page 451 and 452:
croscopic analysis revealed that on
Page 453 and 454:
egg yolk collected from turtles inh
Page 455 and 456:
consistency of results in both expe
Page 457 and 458:
2111 CYTOCHROME P450 3A5 GENOTYPE I
Page 459 and 460:
esidues of organophosphates or thei
Page 461 and 462:
manganism. Recent work from our lab
Page 463 and 464:
Aβ1-40 in CSF and hippocampus in P
Page 465 and 466:
2147 CATALASE MANIPULATIONS MODIFY
Page 467 and 468:
ation based on real-world exposure
Page 469 and 470:
NPs. Aggregation of citrate-stabili
Page 471 and 472:
2175 THE ROLE OF SURFACE CHEMISTRY
Page 473 and 474:
seen rapid uptake in biological ima
Page 475 and 476:
effect on uterine weight or vaginal
Page 477 and 478:
dicating widespread exposure. While
Page 479 and 480:
components into the liver parenchym
Page 481 and 482:
2223 ISOLATION AND DETECTION OF RIC
Page 483 and 484:
stored (-20 celsius degree). The co
Page 485 and 486:
2241 DDA, A BIOMARKER FOR ENVIRONME
Page 487 and 488:
2249 INTERACTION BETWEEN DIETARY SE
Page 489 and 490:
2258 PHARMACOKINETICS, EXCRETION BA
Page 491 and 492:
2267 SENSITIVE AND SPECIFIC FLUORES
Page 493 and 494:
2276 METABOLISM AND DISPOSITION OF
Page 495 and 496:
ment of hypertension in companion a
Page 497 and 498:
for the propyl series can be used f
Page 499 and 500:
2304 IN VITRO EXPOSURE AND EVALUATI
Page 501 and 502:
2313 THE SYNERGISTIC EFFECT OF SODI
Page 503 and 504:
genes that play a crucial role in M
Page 505 and 506:
2330 THE ROLE OF TRANSFORMING GROWT
Page 507 and 508:
ined following up to 96 h continuou
Page 509 and 510:
effect doses obtained with the rat
Page 511 and 512:
diated transcriptional response of
Page 513 and 514:
docrine disruptor activities of EDC
Page 515 and 516:
individuals. Week 6 results were qu
Page 517 and 518:
functionality of photosystem II and
Page 519 and 520:
wild mice (Mus musculus) from areas
Page 521 and 522:
2406 TOXICITY AND BIOACCUMULATION O
Page 523 and 524:
Isocitric acid is the acid in the h
Page 525 and 526:
2425 EFFECTS OF FUMONISINS IN ETHAN
Page 527 and 528:
centration(μg/g) were: 5.1-95.3; 2
Page 529 and 530:
2445 AUTOPHAGY IN DEVELOPMENT: A LI
Page 531 and 532:
sures to inhaled Mn in dust. Nevert
Page 533 and 534:
2466 CRITICAL EVALUATION OF ANIMAL
Page 535 and 536:
elationships predict that resting r
Page 537 and 538:
2489 COMPARATIVE TOXICITY OF BIODIE
Page 539 and 540:
2497 TRANSCRIPTIONAL REGULATION OF
Page 541 and 542:
2506 TOXICOLOGICAL CONSIDERATIONS O
Page 543 and 544:
launched with the aim of developing
Page 545 and 546:
forms mRNA expression levels were a
Page 547 and 548:
2534 CUTANEOUS WOUND HEALING IN THE
Page 549 and 550:
wells (0, 1, 5, 10, 25, 50, 100, an
Page 551 and 552:
2553 AN ORGANOTYPIC MICROLIVER PLAT
Page 553 and 554:
serum-free media. At 24 hrs, the gr
Page 555 and 556:
2572 INCREASED ARSENIC BIOACCESSIBI
Page 557 and 558:
nology to develop improved methods.
Page 559 and 560:
tuna, swordfish, or mako shark (3.5
Page 561 and 562:
nificantly reduce circulating thyro
Page 563 and 564:
grouped into 9 observation periods
Page 565 and 566: histopathological or biochemical ev
Page 567 and 568: exhibited a hyperactive phenotype,
Page 569 and 570: the search of effective drugs for e
Page 571 and 572: 2644 COVALENT BINDING OF 14 C 2-MET
Page 573 and 574: aries targeting all transcription f
Page 575 and 576: (p 9 weeks) and CSC phenotype acqui
Page 577 and 578: 2673 IMMUNE-MEDIATED VASCULAR INJUR
Page 579 and 580: for risk identification and charact
Page 581 and 582: to control toxicant delivery in tob
Page 583 and 584: Author Index (Continued) The numera
Page 611 and 612: Keyword Index (Continued) Arsenite
Page 613 and 614: Keyword Index (Continued) Covalent
Page 615: Keyword Index (Continued) flow cyto
Page 619 and 620: Keyword Index (Continued) nanoparti
Page 621 and 622: Keyword Index (Continued) preservat
Page 623 and 624: Keyword Index (Continued) Thrombocy
Page 625 and 626: Toxicological Sciences The Official
show all

The Toxicologist - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?